Amgen struck multiple European deals to bolster its oncology pipeline, including an acquisition of Dark Blue Therapeutics and a license from Disco Pharmaceuticals. The transactions total up to roughly $1.46 billion and give Amgen access to a preclinical degrader for AML (Dark Blue) and rights to a novel cancer cell‑surface target (Disco). Amgen framed the moves as early investments in targeted degradation and tumor antigen discovery to diversify its cancer R&D.